Form 4: Moleculin Biotech CEO Walter Klemp Reports Stock Transactions
SEC Form 4 Filing
Walter Klemp, CEO and President of Moleculin Biotech, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On June 16, 2024, Walter Klemp, CEO and President of Moleculin Biotech, reported transactions involving Moleculin Biotech, Inc. [MBRX] common stock.
- Klemp acquired 1,667 shares of common stock through the vesting of restricted stock units.
- 406 shares were disposed of to cover tax obligations at a price of $4.14 per share.
- Following these transactions, Klemp directly owns 46,657 shares of common stock and 126,874 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC when a company insider, like the CEO, engages in transactions involving the company's stock. It provides transparency to the market regarding the insider's holdings and transactions.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine compensation and tax obligations of the CEO.
Key Dates
| Date | Description |
|---|---|
| 06/16/2021 | Reporting person was granted 6,668 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. |
| 06/16/2024 | Date of stock transactions: acquisition of 1,667 shares via restricted stock units and disposal of 406 shares for tax obligations. |
| 06/18/2024 | Date of signature on the Form 4 filing. |
Keywords
Moleculin Biotech, MBRX, Walter Klemp, CEO, Form 4, Stock Transaction, Restricted Stock Units, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.